The investigators study aims to determine the effect of prophylactic therapy with Trimethoprim-sulfamethoxazole on the recurrences of toxoplasma retinochoroiditis gondii. This is a randomized, double-masked, in patients with eye condition of acute Toxoplasma gondii retinochoroiditis. Volunteers will be recruited with a previous diagnosis of chorioretinitis presumed Toxoplasma gondii, which show active lesions compatible with recurrence. After the acute phase of treatment of all patients \[1 tablet Trimethoprim-sulfamethoxazole (800/160mg) 12/12h during 45 days\], the same Stratified by gender) will be randomized in a 1:1 ratio between the group 1 - TMP-SMZ (prophylactic treatment with trimethoprim-sulfamethoxazole 1 tablet every other day for 311 days) or group 2 - placebo (consisting of a placebo pill containing no active ingredient of similar appearance to trimethoprim-sulfamethoxazole, 1 tablet every other day for 311 days). The primary outcomes are incidence of episodes of recurrent chorioretinitis by toxoplasmosis in the follow up of 12, 36, 48, 60, 72, 84, 96, 108, and 120 months. Patients will be followed during the ten years in uveitis clinic at intervals defined as follows: return weekly for 4 weeks, then monthly for 2 months, then each 3 months for 9 months, and finally annually for 10 years.
Age range
18 Years – 60 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Incidence of episodes of recurrent chorioretinitis by toxoplasmosis in the follow up of 12 months.
Timeframe: One year
Incidence of episodes of recurrent chorioretinitis by toxoplasmosis in the follow up of 36 months.
Timeframe: Three years
Incidence of episodes of recurrent chorioretinitis by toxoplasmosis in the follow up of 48 months.
Timeframe: Four years
Incidence of episodes of recurrent chorioretinitis by toxoplasmosis in the follow up of 60 months.
Timeframe: Five years
Incidence of episodes of recurrent chorioretinitis by toxoplasmosis in the follow up of 72 months.
Timeframe: Six years
Incidence of episodes of recurrent chorioretinitis by toxoplasmosis in the follow up of 84 months.
Timeframe: Seven years
Incidence of episodes of recurrent chorioretinitis by toxoplasmosis in the follow up of 96 months.
Timeframe: Eight years
Incidence of episodes of recurrent chorioretinitis by toxoplasmosis in the follow up of 108 months.
Timeframe: Nine years
Incidence of episodes of recurrent chorioretinitis by toxoplasmosis in the follow up of 120 months.
Timeframe: Ten years